Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genscript Biotech ( (HK:1548) ) has shared an update.
Genscript Biotech reported that its associate Legend Biotech generated approximately US$597 million in net trade sales from the CARVYKTI® therapy in the quarter ended 31 March 2026, based on figures provided by collaboration partner Janssen Biotech. The sales performance underscores the commercial momentum of CARVYKTI® and may reinforce Genscript’s strategic positioning in advanced cell therapies, though the company cautioned investors about typical sector risks and advised careful consideration when trading its shares.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$15.50 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a Cayman Islands–incorporated biotechnology company listed in Hong Kong, with a focus on biopharmaceutical research and related services. The company holds an associate stake in Legend Biotech Corporation, which is listed on the Nasdaq Global Select Market in the U.S. and collaborates with Janssen Biotech on cell therapy products.
Average Trading Volume: 9,013,158
Technical Sentiment Signal: Sell
Current Market Cap: HK$27.88B
See more data about 1548 stock on TipRanks’ Stock Analysis page.